Vaccination & Infectious Disease Trials

A Track Record in Vaccination and Infectious Disease Trials

EB Medical Research also has experience conducting vaccine studies. These studies are characterized by a relatively high number of visits within a short period, sometimes tied to a specific season.

In the 2023, 2024 and 2025 influenza seasons, EB Medical Research participated in a large influenza vaccine trial, contributing 60 subjects per year. In 2021, EB Medical Research ran a Phase 1/2a UTI vaccine trial with 28 subjects.

EB Medical Research has a proven track record of delivering the required subject numbers on time, reflecting our capability across Phase 1 through Phase 3.

Facility Highlights for Vaccination Studies

Our Almere site is equipped for the operational demands of pharmaceutical trials:

  • Two -80°C ultra-low temperature freezers for long-term sample storage
  • On-site sample processing: centrifuge, pipetting, aliquoting
  • Dedicated clinical research rooms for supervised dosing and monitoring visits
  • On-site ECG and vital signs monitoring equipment
  • All site staff are trained and certified to ICH GCP E6(R3)
  • On-site investigational medicinal product pharmacy,
    a separate unit in the building, operated by a licensed pharmacist (Pharmaserv)
  • Dedicated blinded and unblinded study teams, with the blinded team also responsible for participant-facing procedures such as app and questionnaire instructions.

Subject Recruitment,
a Key Strength

For pharmaceutical studies, timely and reliable recruitment is often the deciding factor for site selection. At EB Medical Research, this is one of our strongest capabilities.

Our database:

  • Approximately 4,500 registered volunteers across the greater Amsterdam–Almere–Gooi region
  • Broad age range; targeted selection by age, health status and availability
  • Proven reach beyond the immediate region, repeat participants from areas at more than 150 km distance

Our approach:

Before recruitment starts, we assess the expected recruitment strategy based on the study’s inclusion and exclusion criteria, subject burden, compensation level and recruitment period. This assessment informs our advice on whether additional support, such as an external recruitment agency, is needed to meet enrollment targets within the required timeline.

We are continuously working to optimize the response to our recruitment calls. A single, concise message with a direct call-to-action and an integrated option to schedule an information call consistently delivers high response rates. For specific age groups or profiles, we activate participant referral, which has reliably filled slots in every study to date.

 

Reference Project

Multicenter Influenza Vaccine Study in Older Adults

Global vaccine manufacturer | Phase 3/3b, randomized, observer-blind, multicenter study | 180 subjects across 3 seasons

A three-season influenza vaccine study (2023/24, 2024/25 and 2025/26) evaluating an adjuvanted subunit inactivated influenza vaccine against a non-adjuvanted comparator in adults aged 65 and older. EB Medical Research enrolled 60 participants in each season, drawing on a highly engaged pool of returning participants from across the country.

 

 “The quality of work was of an exceptionally high standard. I have never seen this before in my entire career.”
Clinical oversight monitor, accompanying the study’s regular monitor

Operational highlights:

  • Delivered 60 vaccinations per season despite shrinking enrollment windows  from delayed IP availability in all seasons to an early sponsor cutoff in 2025/26 that compressed enrollment to just 11 days, including a Sunday clinic to meet the deadline
  • All 180 subjects recruited from EBMR’s own database and a one-time €2,000 advertising budget, without an external recruitment agency
  • Successfully recruited despite annual competition from free influenza vaccination available through Dutch general practitioners
  • Adapted to repeated IP delivery delays each season, rescheduling all affected appointments without losing enrolled subjects
  • Absorbed a same-day request to de-enroll 30 confirmed candidates in 2025/26, offering them a free vaccination outside the study since they had already forgone their free GP vaccination

Why Work with EB Medical Research?

  • Highly experienced
    Extensive experience enables effective communication, short start-up times, and a low likelihood of protocol deviations. 
  • Fast decision-making
    Direct access to the PI and site director for protocol or contract decisions, without layers of internal approval.
  • Dedication and focus on studies
    Clinical trials are our sole business, not a side activity alongside routine patient care. We are driven to achieve the targets set for each study. As a result, sponsors have kept returning to EBMR for new studies for 25 years.
  • Patient orientation
    As a non-treating site, our candidate research participants are central to everything we do. We treat our participants with great care and attention, which is reflected in high retention rates and returning participants.
  • Large candidate database
    Over time, we have built a database of 4,500 research-interested candidates, collected with their consent. Sponsors sometimes assume a hospital- or GP-based site is required to reach their target population. Our database and outreach gives access to that same population directly, as demonstrated in the reference project above.

Let's discuss your study

If you are looking for a reliable site to add to your network, we are happy to discuss feasibility.

We respond within 16 business hours

Request a Feasibility